Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13634541 | 0.94 | OPRK1 (0.40) | OPRK1KMT2AIRAK4PDE4BMAPK1 | |
| SCHEMBL2770731 | 0.93 | OPRK1 (0.42) | OPRK1KMT2AIRAK4MCHR1S1PR1 | |
| Hydrochloric Acid SCHEMBL2770260 | 0.92 | OPRK1 (0.41) | OPRK1KMT2AIRAK4MCHR1S1PR1 | |
| SCHEMBL2772498 | 0.92 | PARP1 (0.43) | OPRK1KMT2AIRAK4MCHR1S1PR1 | |
| SCHEMBL2770473 | 0.91 | KMT2A (0.44) | OPRK1KMT2AIRAK4MCHR1PDE4B | |
| SCHEMBL13634719 | 0.89 | HRH3 (0.39) | OPRK1KMT2AIRAK4MCHR1SMN1; SMN2 | |
| SCHEMBL13634716 | 0.89 | HRH3 (0.40) | OPRK1KMT2AIRAK4SMN1; SMN2 | |
| SCHEMBL13634794 | 0.88 | HRH3 (0.38) | OPRK1KMT2ASMN1; SMN2 | |
| SCHEMBL13634650 | 0.88 | IRAK4 (0.50) | OPRK1KMT2AIRAK4 | |
| SCHEMBL13634617 | 0.88 | MCHR1 (0.39) | OPRK1KMT2AIRAK4MCHR1S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2206707-B1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-30 | — | — | US | disclosed |
| CN-101835764-A | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC | 2010-09-15 | — | — | CN | disclosed |
| EP-2206707-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | TRPV1, FGFR3, GPR17 | OPRK1 534/4885KMT2A 1236/4885IRAK4 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.